Source: OncLive, June 2025
Gino Kim In, MD, a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at Keck School of Medicine of the University of Southern California, discussed the safety and efficacy of superficial and deep or visceral vusolimogene oderparepvec (RP1) injection in a registrational cohort of patients from the phase 3 IGNYTE trial (NCT03767348) with melanoma who progressed on anti–PD-1 inhibitors.
In a post hoc analysis of this study, a cohort of 46 patients with melanoma who achieved a response to RP1 was evaluated to determine whether injected and uninjected lesions demonstrated similar response patterns, In detailed. Up to 10 measurable lesions per patient were analyzed by independent, blinded radiologists to assess response depth, duration, and kinetics, regardless of injection status, In said.